This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

ELIQUIS® (apixaban) dosing for adult with DVT / PE

ELIQUIS for the treatment of DVT / PE and prevention of recurrent DVT / PE

Dosing VTE Dosing VTE

The duration of overall therapy should be individualized after careful assessment of the treatment benefit against the risk for bleeding, as per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).

Duration of overall treatment should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1

No dose adjustment for adult DVT / PE patients, based on weight or those with mild-to-moderate renal impairment.1 ELIQUIS should be used with caution in adult with severe renal impairment (CrCl 15–29 ml/min) for the treatment of DVT / PE and prevention of recurrent DVT / PE.1 ELIQUIS is not recommended in patients with CrCl <15 ml/min, or in patients undergoing dialysis.1

ELIQUIS is a convenient, oral treatment for adult patients

No initial injections or bridging with LMWH required1

ELIQUIS can be taken
with or without food1

Missed dose: A missed morning
dose should be taken immediately
when it is noticed, and it may be
taken together with the evening
dose. A missed evening dose can
only be taken during the same
evening, the patient should not
take two doses the next morning.
The patient should continue with
the intake of the regular dose
twice daily as recommended on
the following day.1

Liver function testing should be performed prior to initiating ELIQUIS1

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1

Footnotes:

  • BD = Twice Daily   CrCl = Creatinine Clearance   DVT = Deep Vein   LMWH = Low Molecular Weight Heparin   PE = Pulmonary Embolism

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com